Compare SRFM & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SRFM | CDXS |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Major Chemicals |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 141.8M |
| IPO Year | 2023 | 2008 |
| Metric | SRFM | CDXS |
|---|---|---|
| Price | $1.16 | $1.96 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $3.25 | N/A |
| AVG Volume (30 Days) | 2.2M | ★ 3.2M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | $106,557,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $25.90 | $6.35 |
| Revenue Next Year | $20.72 | $16.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.30 |
| 52 Week Low | $1.04 | $0.96 |
| 52 Week High | $9.35 | $3.87 |
| Indicator | SRFM | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 69.21 |
| Support Level | $1.04 | $1.57 |
| Resistance Level | $2.16 | $2.13 |
| Average True Range (ATR) | 0.10 | 0.15 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 25.93 | 94.83 |
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.